-
Mashup Score: 0MedAlliance Enrolls First US Patient into its Third FDA IDE Study: SFA SELUTION4SFA - 12 month(s) ago
May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
📢Alert! Women with #superficial vein #thrombosis (SVT) in #pregnancy had a 10.4% risk of having #VTE in that same pregnancy or postpartum period. That is a huge risk justifying treatment of #SVT. @TheLancetHaem Free download until May 13, 2023 https://t.co/jTRd0h4YKe https://t.co/udVjkUr6Em
-
@DAICeditor @MedallianceSA This #study evaluates #SELUTION_SLR in the treatment of occlusive disease of the #superficial #femoral #artery (#SFA) and #proximal #popliteal #artery (#PPA) and has been designed to support #FDA approval: https://t.co/OO6tVXiz5Z